778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma

Registros relacionados

• Lifileucel tumor‐infiltrating lymphocyte cell therapy in patients with unresectable or metastatic mucosal melanoma after disease progression on immune checkpoint inhibitors
  por: Harriet Kluger, et al.
  Publicado em: (2025-10-01)
• Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study
  por: Jessica C Hassel, et al.
  Publicado em: (2022-12-01)
• 778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma
  por: Gino K In, et al.
  Publicado em: (2023-11-01)
• Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Unresectable or Metastatic Melanoma
  por: L. Karapetyan, et al.
  Publicado em: (2026-01-01)
• Cinesia, i comici, Eroziano (PMG 776)
  por: Leonardo Fiorentini
  Publicado em: (2010-12-01)